1145 ET - H. Lundbeck's $2.6 billion deal to buy Longboard Pharmaceuticals underscores the industry's growing in interest in developmental and epileptic encephalopathies, or DEEs, and rare epilepsies, analysts at Truist say. In a research note, Truist says the Longboard deal, which carries a 54% premium, has positive derivative read-throughs to the likes of Praxis Precision Medicines, Marinus Pharmaceuticals and Jazz Pharmaceuticals, all of which have drugs approved or in development for DEE. Praxis up 6.3, Marinus up 2.3% and Jazz up 1.1%. (colin.kellaher@wsj.com)

(END) Dow Jones Newswires

October 14, 2024 11:45 ET (15:45 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.